.jpg)
.png)
All
JACKSONVILLE, Fla. (September 2016) — The Foundation of the National Lipid Association, in conjunction with National Cholesterol Education Month, will launch the RADAR Campaign (RADAR: RAre Disease AwaReness) providing resources and tools to both patients and healthcare professionals designed... more
By Carl E. Orringer A 55-year-old South Asian Indian physician comes to you for management recommendations for primary prevention of atherosclerotic cardiovascular disease (ASCVD). He has no current cardiovascular symptoms. He has an eight-year history of well-controlled arterial hypertension,... more
The US Food and Drug Administration recently announced changes to the safety label for the 80 milligram (mg) dose of simvastatin in the use of cholesterol lowering. The changes are the result of the FDA's review of recent clinical trials including the seven-year Study for the Effectiveness... more
Along with lipid accumulation, inflammation plays a key role in the development of atherosclerosis.(1) Perhaps 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG CoA reductase) inhibitors (statins) are effective in the prevention of atherosclerotic cardiovascular disease (ASCVD) because they... more
Muscle symptoms in patients on statin therapy are prevalent and offer a complicated differential for providers to entertain. Symptoms range from relatively mild aches and pains to severe and debilitating weakness and pain. Statins are taken by more than 25 million patients across the globe and have... more
From TheHeart.org: Amsterdam, the Netherlands - An analysis of four phase-2 studies testing the effectiveness of AMG145 (Amgen), a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), showed the drug reduces LDL cholesterol by 43% to 64%, depending on the... more
The National Lipid Association (NLA) today announced the publication of a new meta-analysis evaluating the impact of low-density lipoprotein cholesterol (LDL-C) lowering on major adverse cardiovascular events (MACE) in primary prevention populations. The study synthesizes data from randomized... more
Risk assessment tools and lifestyle surveys can play a major role in screening patients for risk of atherosclerotic cardiovascular disease (ASCVD), allowing for early targeted interventions. It is known that race can greatly impact risk, yet it isn’t incorporated in all risk calculators. Similarly... more
Abstract This case illustrates a common presentation of a rare phenomenon that should be highlighted so that clinicians are aware of the signs, implications, and management of LpX syndrome. Patient XY is a 30-year-old nonsmoker who was referred to our lipid clinic because of newly recognized... more